Literature DB >> 9554880

Conformation-function relationship of vitamin D: conformational analysis predicts potential side-chain structure.

S Yamada1, K Yamamoto, H Masuno, M Ohta.   

Abstract

In previous studies, we have grouped regions in space occupied by the vitamin D side chain into four: A, G, EA, and EG. We showed that the receptor (VDR) affinity of 1alpha,25-dihydroxyvitamin D3 derivatives increases, in terms of side-chain region, in the order EG, G, A, and EA. We called this the active space group concept. In the present study, we used this active space group concept to analyze the conformation-activity relationship of about 40 representative potent 1alpha,25-dihydroxyvitamin D3 analogues. We initially listed structural modifications in the side chain of potent vitamin D analogues and estimated their potency factor. Possible side-chain conformations of representative analogues were calculated by the molecular mechanics method and plotted on a dot map compared with the regions A, G, EA, and EG. The cell-differentiating potency of the analogues was correlated with our active space group concept with few exceptions. Among potent analogues with a natural configuration at C(20), the side chains of those with a 22-oxa, 22-ene, 16-ene, or a 18-nor modification were located in front of region EA (termed F). The side chains of the most potent 20-epi-22-oxa-24-homovitamin D analogues were concentrated at the left side of the EA region (L-EA). Thus, the side chains of almost all potent analogues were distributed around the EA region, and potency increased in the order A, F, EA, and L-EA.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9554880     DOI: 10.1021/jm970761l

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  7 in total

1.  New insights into Vitamin D sterol-VDR proteolysis, allostery, structure-function from the perspective of a conformational ensemble model.

Authors:  Mathew T Mizwicki; Craig M Bula; June E Bishop; Anthony W Norman
Journal:  J Steroid Biochem Mol Biol       Date:  2007-03       Impact factor: 4.292

2.  A molecular description of ligand binding to the two overlapping binding pockets of the nuclear vitamin D receptor (VDR): structure-function implications.

Authors:  Mathew T Mizwicki; Danusa Menegaz; Sepideh Yaghmaei; Helen L Henry; Anthony W Norman
Journal:  J Steroid Biochem Mol Biol       Date:  2010-04-14       Impact factor: 4.292

3.  Three-dimensional modeling of and ligand docking to vitamin D receptor ligand binding domain.

Authors:  K Yamamoto; H Masuno; M Choi; K Nakashima; T Taga; H Ooizumi; K Umesono; W Sicinska; J VanHooke; H F DeLuca; S Yamada
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-15       Impact factor: 11.205

4.  Bioengineering anabolic vitamin D-25-hydroxylase activity into the human vitamin D catabolic enzyme, cytochrome P450 CYP24A1, by a V391L mutation.

Authors:  Martin Kaufmann; David E Prosser; Glenville Jones
Journal:  J Biol Chem       Date:  2011-06-22       Impact factor: 5.157

5.  A 20S combined with a 22R configuration markedly increases both in vivo and in vitro biological activity of 1α,25-dihydroxy-22-methyl-2-methylene-19-norvitamin D3.

Authors:  Agnieszka Flores; Rafal R Sicinski; Pawel Grzywacz; James B Thoden; Lori A Plum; Margaret Clagett-Dame; Hector F DeLuca
Journal:  J Med Chem       Date:  2012-04-22       Impact factor: 7.446

6.  Computer-aided de novo ligand design and docking/molecular dynamics study of vitamin D receptor agonists.

Authors:  Xiu-Long Shen; Midori Takimoto-Kamimura; Jing Wei; Qing-Zhi Gao
Journal:  J Mol Model       Date:  2011-04-27       Impact factor: 1.810

7.  Vitamin D Analogs Bearing C-20 Modifications Stabilize the Agonistic Conformation of Non-Responsive Vitamin D Receptor Variants.

Authors:  Anna Y Belorusova; Daniela Rovito; Yassmine Chebaro; Stefanie Doms; Lieve Verlinden; Annemieke Verstuyf; Daniel Metzger; Natacha Rochel; Gilles Laverny
Journal:  Int J Mol Sci       Date:  2022-07-30       Impact factor: 6.208

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.